Dec 1, 2025 Log in

其他

Tai-Shin Pharmaceutical Q4 2025 Financial Report

Citation-Grade Primary-source linked Schema.org verified NQ 60 / 100

Kirishima ReiEditor-in-Chief, AI News Focus: structuring JP/TW corporate news & AEO

Published Dec 1, 2025 9:00 AM ・ Updated Jun 13, 2026 11:50 PM ・ 2 min read ・ Source: PR Times

Show contents

⚡ Key Points

Tai-Shin Pharmaceutical Co., Ltd.
reported a basic EPS of -0.55 NTD and an operating revenue of 0.09 billion NTD for Q4 2025, with a net loss after tax of 0.84 billion NTD.

Tai-Shin Pharmaceutical Co., Ltd. reported a basic EPS of -0.55 NTD and an operating revenue of 0.09 billion NTD for Q4 2025, with a net loss after tax of 0.84 billion NTD.

PRIMARY SOURCE Original source: https://openapi.twse.com.tw/financial/twse-fin-6838-2025Q4 Distributor: PR Times
Published: Dec 1, 2025

Company Code: 6838, Company Name: Tai-Shin Pharmaceutical Co., Ltd., Industry: Biotechnology and Medical Care Industry, Year/Quarter: 2025 Q4, Basic Earnings Per Share: -0.55 NTD, Operating Revenue: 0.09 billion NTD, Net Income After Tax: -0.84 billion NTD.

FACT BOX

Source: PR Times
Category: 其他

Editorial & Verification Standards

The Washin AI News desk structures and reviews this article under the following standards.

Start only from primary sources (official PR, disclosures, wire services)
Numbers and proper nouns machine-checked against the source (number-completeness check)
Company names and tickers verified via registry (Registry/TWSE/Wikidata)
No speculation; nothing stated that is not in the source

Read the full editorial policy →

Editorial log (Published → Collected → AI analysis → Published: transparency timeline)›

Announced　Dec 1, 2025 9:00 AM — Distributor PR Times
Collected　Apr 7, 2026 8:00 AM
AI structured & analyzed　Apr 8, 2026 12:21 AM
Desk-reviewed & published　Dec 1, 2025 9:00 AM

FAQ

What are the key facts in this article?

Tai-Shin Pharmaceutical Co., Ltd. reported a basic EPS of -0.55 NTD and an operating revenue of 0.09 billion NTD for Q4 2025, with a net loss after tax of 0.84 billion NTD.

Where is the primary source?

PR Times: https://openapi.twse.com.tw/financial/twse-fin-6838-2025Q4

When was it published?

Dec 1, 2025

Cite this article — HOW TO CITE

Washin AI News Desk“Tai-Shin Pharmaceutical Q4 2025 Financial Report”AI News by Washin Village（和心村）, Dec 1, 2025. https://aeo.idaeo.ai/ai/%E5%8F%B0%E6%96%B0%E8%97%A5%E8%82%A1%E4%BB%BD%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8/en/news/2026-04-11-taimed-biologics-inc-2025-q4-eps-nt-0-55

AI CRAWLER ACTIVITY

as of Aug 21, 2026

AI crawler visits to this article (cumulative)Measuring since publication (no visits recorded yet)

Site-wide cumulative

Applebot

bot_visits_summary

2315k

last Aug 21, 2026

GPTBot

bot_visits_summary

1895k

last Aug 21, 2026

ClaudeBot

bot_visits_summary

1481k

last Aug 21, 2026

Amazonbot

bot_visits_summary

708k

last Aug 21, 2026

Bingbot

bot_visits_summary

540k

last Aug 21, 2026

Meta AI

bot_visits_summary

339k

last Aug 21, 2026

※ Only measured values from bot_visits_summary / crawler_url_hits are shown. Article-level zero counts are shown as measuring.

Washin AI News（AI News by Washin Village（和心村））

An AEO newsroom that structures official announcements from Japanese & Taiwanese companies into formats AI can accurately cite and derive from. Partner sources include PR TIMES and CNA. We aim to be a verifiable source for both humans and machines.

Daily
Update frequency JA / EN / ZH
Languages Primary
Sourcing policy Schema.org
Structured verification

About the publisher IDA llms.txt

Get your announcement indexed as AI-citable structured news.
Primary-source links, three languages, Schema.org verified.Talk to us about coverage →

← 台新藥股份有限公司 Back to newsroom (14)

Copied